Fresenius And Wuxi Biologics Enter Exclusive Development Agreement To Expand Biosimilars Pipeline

Nov 2 (Reuters) -

• FRESENIUS AND WUXI BIOLOGICS ENTER EXCLUSIVE DEVELOPMENT AGREEMENT TO EXPAND BIOSIMILARS PIPELINE

• FRESENIUS WILL DETERMINE LONG-TERM MANUFACTURING STRATEGY FOR EACH CANDIDATE, WITH OPTIONALITY TO LEVERAGE MABXIENCE NETWORK, WHOLLY OWNED SINCE OCTOBER 2026

• AGREEMENT GIVES FRESENIUS FULL STRATEGIC FLEXIBILITY TO SELECT AND ADVANCE BIOSIMILAR CANDIDATES TO DEVELOP, AGAINST ITS ESTABLISHED SELECTION CRITERIA, WHILE RETAINING FULL COMMERCIALIZATION ECONOMICS OF PRODUCTS UNDER AGREEMENT

• EXCLUSIVE OPTION RIGHTS FOR UP TO 37 POTENTIAL FIRST-TO-MARKET BIOSIMILAR CANDIDATES TO SIGNIFICANTLY EXPAND FRESENIUS' PORTFOLIO

• NEXT-GENERATION PORTFOLIO SPANS 13 THERAPEUTIC AREAS AND MULTIPLE BIOLOGIC TECHNOLOGIES, INCLUDING MONOCLONAL AND BISPECIFIC ANTIBODIES, ANTIBODY-DRUG CONJUGATES AND FUSION PROTEINS

• PROVIDES ACCESS TO INCREASE PORTFOLIO FROM 29 MARKETED AND PIPELINE MOLECULES TODAY TO UP TO 66 MOLECULES

• IT PROVIDES ACCESS TO A SCALABLE PATHWAY TO INCREASE PORTFOLIO , ADDRESSING MORE THAN EUR 370 BILLION IN ORIGINATOR LIST-PRICE-BASED-SALES

Further company coverage: FREG.DE